Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) has shared an update.
Jubilant Pharmova Limited’s subsidiary, Jubilant Biosys Limited, has received three Orders-in-Appeal from the Additional Commissioner Central Tax (Appeals) in Mysuru, disallowing previously sanctioned GST refunds totaling Rs. 43.83 crore. The company plans to appeal these orders, arguing that the rulings are legally incorrect due to the omission of Rule 89(4B) from the CGST Rules and expects no financial or operational impact from this development.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the pharmaceutical industry, primarily focusing on the development and manufacturing of a wide range of pharmaceutical products. The company has a significant market presence and engages in various aspects of the pharmaceutical supply chain.
Average Trading Volume: 14,368
Technical Sentiment Signal: Buy
Current Market Cap: 162.4B INR
For detailed information about JUBLPHARMA stock, go to TipRanks’ Stock Analysis page.